Peptides Corresponding to the Receptor‐Binding Domain (RBD) of Several SARS‐CoV‐2 Variants Of Concern Prevent Recognition of the Human ACE2 Receptor and Consecutive Cell Infections
ChemMedChem · 2025
DOI: 10.1002/cmdc.202400973 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Mandy Schwarze und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, Leipzig, Germany. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Peptides. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, the European Regional Development Fund (ERDF) and the Free State of Saxony, Deutsche Forschungsgemeinschaft (DFG), co-financed by tax funds on the basis of the budget passed by the Saxon state parliament.
Abstract (Originalsprache)
New strategies are needed to prevent and control upcoming outbreaks of SARS‐CoV‐2 infections, independent of vaccination. SARS‐CoV‐2 binds to the human ACE‐2 receptor through the receptor binding domain (RBD) of the spike (S) protein, allowing the virus to enter human cells and begin replication. When peptides corresponding to four regions of RBD containing previously reported ACE‐2 interaction sites were explored, the sequence 392 to 421, peptide p392wt, bound strongly to ACE‐2 and inhibited wild‐type RBD binding to ACE‐2. Interestingly, p392 peptides corresponding to mutated sequences from different SARS‐CoV‐2 VOCs, including the current VOC BA.5 and KP.3, bound less strongly to ACE‐2, but showed partially better inhibition of the ACE‐2 interaction of all tested RBDs. When studied in a SARS‐CoV‐2 pseudovirus assay, the p392 peptides showed a good inhibition rate of 98.8±8.1 % at a peptide concentration of ~244 μmol/L, while none of the p392 peptides inhibited antibody binding to the RBD, suggesting that peptide treatment is sufficient in the presence of anti‐RBD antibodies. Interestingly these peptides were active in the presence of diluted human serum and non‐toxic to human cell lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, Leipzig, Germany.
- Center for Biotechnology and Biomedicine, Leipzig University, Leipzig, Germany.
ORCID-Profile: Mandy Schwarze, Alexandra Brakel, Ralf Hoffmann
Förderung
- European Union, the European Regional Development Fund (ERDF) and the Free State of Saxony
- Deutsche Forschungsgemeinschaft (DFG)
- co-financed by tax funds on the basis of the budget passed by the Saxon state parliament
- German Research Foundation within the program Open Access Publication Funding
Zitieren
APA
Schwarze, M., Brakel, A., Hoffmann, R., & Krizsan, A. (2025). Peptides Corresponding to the Receptor‐Binding Domain (RBD) of Several SARS‐CoV‐2 Variants Of Concern Prevent Recognition of the Human ACE2 Receptor and Consecutive Cell Infections. ChemMedChem. https://doi.org/10.1002/cmdc.202400973
Vancouver
Schwarze M, Brakel A, Hoffmann R, Krizsan A. Peptides Corresponding to the Receptor‐Binding Domain (RBD) of Several SARS‐CoV‐2 Variants Of Concern Prevent Recognition of the Human ACE2 Receptor and Consecutive Cell Infections. ChemMedChem. 2025. doi:10.1002/cmdc.202400973
BibTeX
@article{Schwarze2025,
author = {Schwarze, Mandy and Brakel, Alexandra and Hoffmann, Ralf and Krizsan, Andor},
title = {Peptides Corresponding to the Receptor‐Binding Domain (RBD) of Several SARS‐CoV‐2 Variants Of Concern Prevent Recognition of the Human ACE2 Receptor and Consecutive Cell Infections},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202400973}
}
EUVIMED